ArticleNeuro-oncology2019

A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.

Ekaterina Pak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.